<DOC>
	<DOC>NCT01456052</DOC>
	<brief_summary>This is a multicenter, placebo-controlled, parallel-group, pilot study to evaluate safety and preliminary effectiveness of two blinded dose levels of LX1606 in subjects with acute, mild to moderate ulcerative colitis on 5-aminosalicylic acid/mesalamine therapy.</brief_summary>
	<brief_title>A Study to Evaluate Safety and Efficacy of LX1606 in Subjects With Acute, Mild to Moderate Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Diagnosis of ulcerative colitis of at least 6 months duration Disease extends at least 15 cm proximally from the anal verge, documented within the past 3 years Flare occurs on 5aminosalicylic acid (5ASA)/mesalamine therapy and subject is willing to remain on a stable dose for the duration of the study Age â‰¥18 and &lt;70 years of age Able and willing to provide written informed consent Prior terminal ileum or colonic surgery, except appendectomy or hemorrhoid surgery Presence of indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, or clinical findings suggestive of Crohn's disease Clinical signs of fulminant colitis or toxic megacolon History of dysplasia associated lesion or mass (DALM) Subjects who have had surgery for ulcerative colitis, or in the opinion of the investigator, are likely to require surgery for ulcerative colitis during the study History of primary sclerosing cholangitis Any physical or laboratory abnormality deemed by the investigator as clinically significant Major surgery within 60 days of Screening Use of any investigational agent within 30 days of Screening or any therapeutic protein or antibody within 90 days of Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>